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Background: Cardiac myosin binding protein-C (cMyBP-C) regulates sarcomeric structure, as well as myocardial contractility, and its 
phosphorylation is known to confer cardioprotection. We recently showed that cMyBP-C is an easily releasable and soluble myofilament, 
dephosphorylation of cMyBP-C results in its degradation and release into the blood post-myocardial infarction and plasma cMyBP-C levels are 
significantly increased in animal models and patients with myocardial infarction (MI).
Hypothesis: Plasma levels of cMyBP-C could be an important biomarker for MI in acute coronary syndrome (ACS) patients.
Methods and Results: We examined a total of 96 subjects (sample collected at the time of hospital admission) and 56 subjects (24 hrs), 
17 subjects (6 weeks) and 32 subjects (6 months) of post-intervention subjects with ACS, compared with 70 normal healthy controls samples. 
In addition, we used plasma samples from ACS patients who undergo percutaneous coronary intervention (NICE1 study- National Investigators 
Collaborating on Enoxaparin, n=99) and end stage renal disease (n=70). Plasma cMyBP-C, cardiac troponin I (cTnI), myoglobin, creatine kinase-
MB (CK-MB), glycogen phosphorylase BB (GP-BB), heart type-fatty acid binding protein (h-FABP), carbonic anhydrase 3 (CA3) protein profiles were 
measured by sandwich ELISA and Randox cardiac plus arrays. Plasma cMyBP-C levels were significantly higher in patients with ACS than in healthier 
normals (ACS vs. healthier: 339 ± 38 ng/mL vs. 22 ± 2 ng/mL, P < 0.001). Patients with ACS had higher levels of cTnI, CK-MB, h-FABP, GP-BB and 
CA3 than healthier controls (P <0.001). After subgrouping the ACS patients with post-intervention therapy, we found that plasma cMyBP-C levels 
declined over 6 weeks of time point. Immunoprecipitation analyses confirmed the presence of cMyBP-C and its fragments in the plasma samples of 
patients with ACS. These results provide further evidence that cMyBP-C is a promising biomarker for MI.
Summary: Our findings suggest that circulating cMyBP-C represents a novel potential marker of ACS and therapeutic efficacy and that augmented 
cMyBP-C levels could provide an underlying MI-induced proteolytic mechanism in ACS.
